Cocrystal Pharma, Inc.COCPNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P29
Within normal range
vs 5Y Ago
-0.9x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2024-10.83%
20234.26%
20225.86%
2021-2.50%
202014.46%
201911.74%
201878.36%
2017-41.06%
2016-38.80%
2015289.46%